These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7130430)

  • 1. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone.
    McInnes GT; Asbury MJ; Ramsay LE; Shelton JR; Harrison IR
    J Clin Pharmacol; 1982; 22(8-9):410-7. PubMed ID: 7130430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing comparative bioavailability of spironolactone tablets.
    Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
    J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone. II. Bioavailability.
    Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
    Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
    Bartle WR; Coates PE; Fisher MM; Louman FJ
    Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
    Tidd MJ; Collins WT; Chamberlain J
    J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo availability of spironolactone from oral dosage forms.
    Chao AY; Sanvordeker DR; Zagarella J; Mattes K; Nicholova B; Karim A
    J Pharm Sci; 1976 Nov; 65(11):1630-4. PubMed ID: 993995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bioavailability of two new preparations of spironolactone tablets.
    Nijkerk AJ; Vermeer JM; Imanse M; De Vos D
    Pharm Weekbl Sci; 1983 Oct; 5(5):210-2. PubMed ID: 6646986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intersubject comparison of the bioavailability of spironolactone in 2 pharmaceutical dosage forms].
    Lucchelli PD; Monarca A; Del Mastro S; Sega R
    Boll Chim Farm; 1978 Aug; 117(8):487-95. PubMed ID: 743391
    [No Abstract]   [Full Text] [Related]  

  • 10. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bioavailability of spironolactone hydrochlorothiazide combination preparation.
    Rameis H; Hitzenberger G; Horwatitsch H
    Int J Clin Pharmacol Ther Toxicol; 1982 Jul; 20(7):327-33. PubMed ID: 7107086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved bioavailability from a spironolactone beta-cyclodextrin complex.
    Yusuff NT; York P; Chrystyn H; Bramley PN; Swallow RD; Tuladhar BR; Losowsky MS
    Eur J Clin Pharmacol; 1991; 40(5):507-11. PubMed ID: 1884726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bioavailability studies of two spironolactone-preparations (author's transl)].
    Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
    Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma uric acid and spironolactone response in healthy subjects.
    Ramsay LE; Shelton JR; Harrison IR
    Br J Clin Pharmacol; 1977 Apr; 4(2):247-9. PubMed ID: 861142
    [No Abstract]   [Full Text] [Related]  

  • 16. Application of a simple fluorometric method on absorption of canrenone.
    Radó JP; Szende L; Takó J; Nagy O; Kozma C
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
    Krause W; Karras J; Seifert W
    Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolism and biopharmaceutics of spironolactone in man.
    Overdiek HW; Merkus FW
    Rev Drug Metab Drug Interact; 1987; 5(4):273-302. PubMed ID: 3333882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
    Rosenthal J; Jaeger H; Specker M
    Arzneimittelforschung; 1979; 29(9):1428-32. PubMed ID: 583254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.